SUMMARY
Activation of endogenons complement is inhibited both in the solnble phase and at the membrane surface by a group of structurally similar proteins. A possible solution to hyperacute rejection is to produce donor animals transgenic for human complement regulators. Mouse cells expressing the human complement regula tory proteins decay accelerating factor (DAF) or membrane cofactor protein (MCP) were produced both by hybridoma technology and by transfection with the appropriate cDNAs. The expression of either or both of these products protected the mouse cell from lysis by human (though not rabbit) complement in the presence of naturally occurring human anti-mouse antibody. This effect could be abrogated by the addition of monoclonal antibody against DAF or MCP. Hyperacute rejection of discordant organ xenografts is mediated by human complement. A 6.5 kilobase minigene for DAF has been microinjected into porcine fertilised ova. Forty-five pigs transgenic for human DAF have been produced. Of these, 65% transcribe message. The amount of message produced varied substantially from animal to animal and was independent of copy number integrated. Expression of human DAF on the porcine lymphocyte surface could be detected and this was able to downregulate human complement activation. Amounts of protein expressed on different tissues varied both from pig to pig and within animals from tissue to tissue. The pigs grow and develop normally with no evidence of ill effects due to possession of the trans gene.
Vascular grafts transplanted between distantly related species are hyperacutely rejected minutes after revascularisation. Numerous investigations have demonstrated that complement is critically involved in this process,1,2 although the precise mechanisms by which this occurs are poorly under stood. Platt et at? have demonstrated that pig endothelium can be activated as assessed by the release of heparin sulphate by the fixation of C3b via the classical pathway. Forty and co-workers4 have demonstrated that platelet thrombus formation induced by classical pathway activation of comple ment causes rapid failure of rabbit hearts perfused with human blood. However, both Forti' and others6-8 have also demonstrated a role for the alternative pathway of complement in hyperacute xenograft rejection. The enzymatic cleavage of C3 by the C3 convertases is a key step in complement mediated destruction via both pathways and is regulated by a family of proteins termed the regulators of complemented activation (RCA).9 This family includes serum proteins (factor H and C4 binding protein), receptors (CRl and CR2) and the membrane-bound proteins decay accelerating factor (DAF) and membrane cofactor protein (MCP).
Since DAF and MCP are believed to protect autologous tissue from endogenous complement activation, tO we sought to determine whether these human proteins could protect discordant mammalian cells from human complement-mediated destruction. These regulators of complement activation (RCAs) are, to a large extent, species specific. Transferring human RCA products to the membranes of animal tissues either biochemically or by transfection should confer protection against human complement on the animal tissue to a degree which may be sufficient to inhibit hyperacute rejection. Work has now pro gressed from tissue culture studies to encompass the whole animal. Here we describe the production of pigs transgenic for human DAF, the relationship between transcription and expression and the degree to which expression can protect the transgenic pig tissue from lysis by human complement.
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MATERIALS AND METHODS
Human/mouse cell hybrids generated by fusion of human Epstein-Barr virus (EBV)-transformed B cells with the non-secreting mouse myeloma X63-Ag8.65311 were screened for the presence of human chromosome 1. This was performed by hybridisation with oligonucleotide primers specific for human chromosome 1 following polymerase chain reaction (PCR) amplification of DNA extracted from cell lines. Both upstream (5' -CCACAGGTGT AA CATTCTGT-3') and downstream (5'-GAGA TAGTGTGATCTGAGGC-3') primers were from the sequence of human anti-thrombin II (AT3) geneY A human/mouse hybridoma, BI0 (which secretes human anti-tetanus antibody: N. Hughes Jones, personal communication), retained human chromosome 1. An EBV-transformed human tonsi lar B cell line, T5, and a mouse/mouse hybridoma, DB3 (also produced by fusion with X63-Ag8.65313), were used as negative and positive controls respec tively.
Chromium release assay was performed as previously described.14 Complement was absorbed at +4°C with mouse spleen cells (2 ml per spleen) to remove lytic naturally occurring anti-mouse anti bodies. Human or pig serum was used as a source of naturally occurring antibodies and was heat-inacti vated at 56°C for 30 minutes. Monoclonal antibodies were added to labelled cells immediately prior to the start of the assay at 10 IJ-glml.
Mouse fibroblasts were transfected with DAF and MCP cDNAs subcloned in the forward orientation into the EcoRI site of the expression vector pHBapr I_neo.15 An additional construct, in which the MCP sequences were cloned into the expression vector in the reverse orientation, was isolated and used as a control. Cloned cDNA for DAF and MCP was obtained and characterised as previously described.16,17 Plasmid DNA was prepared using the pZ523 kit (5'-3' Inc., West Chester, PA, USA). NIH 3T3 cells were transfected utilising Lipofectin (Bethesda Research Laboratories, Gaithersburg, MD, USA) and then cultured for 2 days in Dulbecco-modified Eagle's medium supplemented with 10% horse serum following which Geneticin (Gibco, Grand Island, NY, USA) was added to the medium at an active concentration of 0.5 mg/ml. Cells were subsequently maintained in this medium. DAF transfectants were further selected by fluores cence-activated cell sorting (EPIC 75, Coulter Corp., Hialea, FL, USA).
Production of Transgenic Pigs
Pronuclear-stage embryos were collected by mid ventral laparotomy from the oviducts of 7-to 10-month-old mature gilts 49-52 hours after super ovulation, the gilts having been inseminated 20 and
26 hours earlier. Visualisation of the pronucleus was achieved by centrifugation of the ova at 15000g for 3 minutes. These ova were then microinjected using an inverted microscope with Nomarski optics and micromanipulaors. DNA was injected until the ova increased their diameter by approximately 50%. Injected ova were transferred surgically to both oviducts of recipient gilts whose oestrous cycles were either synchronous with or 24 hours behind those of the donors.
A total of 2443 ova microinjected with the DAF minigene were transferred to recipient gilts. Of these, 49 (65%) produced 311 offspring. Forty-six (14.8%) of these offspring were identified by dot and southern blot analysis (using DNA isolated from ear biopsy samples) as having incorporated into their genome between 1 and 30 copies of the DAF minigene per cell. Expression of the trans gene in the peripheral blood mononuclear cells was deter mined by RT-PCR using primers designed to span an intron/exon boundary and by Northern analysis. Messenger RNA for human DAF was detected in 67% of the transgenic pigs. The level of RNA varied from pig to pig and was found to be independent of the number of genes integrated into the genome, sex or growth rate.
RESULTS
Fluorescence-activated cell sorting (F ACS) analysis using the monoclonal antibodies lAI0(17) and E4.3 (20) showed that the selected human/mouse hybrid, BlO, expressed both human DAF and MCP, as did the human tonsilar cell line T5. The mousel mouse hybrid did not express these RCA products. Fig. la shows that naturally occurring human anti mouse antibodies and human complement were able to lyse DB3, (the mouse/mouse hybridoma) but not BlO (the human/mouse hybridoma). Both cell types were killed by rabbit complement (Fig. Ib) . T5 exposed to pig anti-human antibodies was lysed in the presence of rabbit complement but not human complement (data not shown).
Cell lines transfected with the DAF -or MCP constructs were isolated and shown by F ACS analysis to be expressing DAF or MCP. The MCP transfectant (unsorted) expressed approximately 1 X 106 copies per cell (in the range of a malignant epithelial cell linel8) while the DAF transfectant (sorted twice) expressed approximately 30 000 copies per cell, similar to a normal peripheral nucleated cell. The cytoprotective effect of transfecting the indivi dual genes for DAF or MCP was tested by treating all three cell lines (the two expressing cell lines and the control transfected in the reverse orientation) with human complement and naturally occurring human anti-mouse antibodies. The mouse fibroblasts expressing human DAF (Fig. 2a) or MCP (Fig. 2b) . 
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Expression of DAF Protein on Lymphocytes
Pigs transgenic for human DAF (hDAF) were studied for the expression of protein on the surface of their peripheral blood mononuclear cells (PBMC)
by radioimmunoassay (Fig. la) . hDAF could be detected in 84% of pigs producing RNA. No protein was found in RNA-negative animals. hDAF expres sion on the cell surface of PBMC varied considerably from pig to pig. The transgenic pig with the highest hDAF levels (ASO) exhibited a fivefold lower expression compared with that seen on human PBMC (Fig. 3) . (Fig. 4). D. J. G. WHITE ET AL. 
Expression of hDAF in Other Tissues
Production of transgenics requires that founder animals be retained for breeding and that the offspring be appropriately backcrossed to produce homozygotes. However, during the course of these studies three transgenics have been killed, giving access to other tissues for analysis. 
DISCUSSION
A precise understanding of the steps of the complement reaction that participate in hyperacute xenograft rejection will be needed to design ap�ro priate strategies for therapeutic intervention. 
